Medico Intercont Peer Comparison

BSE: 539938

₹25.48

₹0.32 (1.27%)

As on 06-Nov-2026IST

Market cap

₹25 Cr

Revenue (TTM)

₹83 Cr

P/E Ratio

--

P/B Ratio

0.6

Div. Yield

0 %

Edit

	Medico Intercont	Piramal Pharma	Wockhardt	Acutaas Chemicals	Rubicon Research
Market cap (₹ Cr)	25	31,846	31,626	31,006	27,455
Revenue (₹ Cr)	83	9,779	3,751	1,593	2,100
Net Profit (₹ Cr)	-12.64	-270.51	405.00	438.64	324.79
Net Margin (%)	-14.95	-2.71	10.48	27.16	15.36
RoE (%)	-8.39	-2.55	7.91	25.02	24.02
Price to Earnings	--	--	77.14	70.61	84.52
Price-To-Book	0.60	3.91	6.13	16.69	20.45

Income Statement
Liabilities
Assets
Cashflow
Ratios

Income Statement (₹ Cr)

	Medico Intercont	Piramal Pharma	Wockhardt	Acutaas Chemicals	Rubicon Research
Operating Revenue	83.44	9,778.62	3,751.00	1,592.52	2,100.17
Total Income	84.58	9,993.26	3,863.00	1,615.23	2,114.53
Total Expenditure	81.83	8,578.44	2,984.00	969.32	1,600.14
EBITDA	1.61	1,200.18	767.00	623.20	500.03
Depreciation	6.02	887.82	228.00	41.96	57.00
EBIT	-4.41	312.36	539.00	581.24	443.03
Interest	7.71	347.94	218.00	4.21	40.83
Other Income	1.14	214.64	112.00	22.71	14.37
Exceptional Items	0.00	-216.88	12.00	0.00	0.00
Profit before Tax	-10.98	-37.82	445.00	599.74	416.57
Provision for Tax	1.66	232.69	40.00	161.10	91.78
Profit after Tax	-12.64	-270.51	405.00	438.64	324.79

Liabilities (₹ Cr)

	Medico Intercont	Piramal Pharma	Wockhardt	Acutaas Chemicals	Rubicon Research
Shareholder's Funds	46.89	8,142.24	5,158.00	1,857.45	1,416.33
Minority Interest	8.56	0.55	5.00	0.51	0.05
Non-Current Liabilities	47.25	5,213.99	1,617.00	47.15	376.76
Current Liabilities	37.74	5,158.51	1,785.00	253.37	952.98
Total Liabilities	75.76	15,513.53	8,100.00	1,549.26	1,451.43

Assets (₹ Cr)

	Medico Intercont	Piramal Pharma	Wockhardt	Acutaas Chemicals	Rubicon Research
Non-Current Assets	54.63	10,687.30	5,527.00	1,132.12	798.30
Current Assets	61.25	7,253.65	2,764.00	1,012.00	1,747.21
Total Assets	75.76	15,513.53	8,100.00	1,549.26	1,451.43
Total Debt*	16.92	4,720.27	1,859.00	8.18	393.17
Net Current Assets	23.51	2,095.14	979.00	758.64	794.23
Contingent Liabilities	4.79	99.76	770.26	15.38	12.25

Cashflow (₹ Cr)

	Medico Intercont	Piramal Pharma	Wockhardt	Acutaas Chemicals	Rubicon Research
Cash From Operating Activities	-7.11	892.30	-22.00	118.34	159.18
Cash Flow from Investing Activities	-2.19	-477.46	-783.00	-223.94	-64.81
Cash from Financing Activities	8.63	-440.83	409.00	261.12	-39.81
Net Cash Inflow / Outflow	-0.68	-25.99	-396.00	155.52	54.56

Ratios

Profitability Ratios

	Medico Intercont	Piramal Pharma	Wockhardt	Acutaas Chemicals	Rubicon Research
ROCE (%)	13.81	6.61	4.07	20.14	26.97
ROE (%)	-8.39	-2.55	7.91	25.02	24.02
ROA (%)	-13.10	-1.56	4.65	22.40	14.30
EBIT Margin (%)	-5.28	3.19	14.37	36.50	21.09
Net Margin (%)	-14.95	-2.71	10.48	27.16	15.36
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

Growth Ratios

	Medico Intercont	Piramal Pharma	Wockhardt	Acutaas Chemicals	Rubicon Research
Revenue Growth (%)	-14.32	9.43	25.70	45.18	46.25
EBIT Growth (%)	-174.76	-3.72	139.56	115.51	60.95
Net Profit Growth (%)	-1,032.92	-199.34	894.12	95.80	89.41
EPS Growth (%)	-220.52	-410.28	599.72	63.29	76.32
Book Value Growth (%)	8.03	2.28	29.77	94.96	42.49

Valuation Ratios

	Medico Intercont	Piramal Pharma	Wockhardt	Acutaas Chemicals	Rubicon Research
Price / Earnings	-6.42	-153.14	79.16	70.61	84.35
Price / Book Value	0.60	3.91	6.13	16.69	20.45
Dividend Yield (%)	0.00	0.00	0.00	0.07	0.09
EV/EBITDA	24.62	29.98	43.14	49.43	54.73
Market Cap (₹ Cr)	35.47	29,731.27	23,064.69	19,988.69	0.00

Solvency Ratios

	Medico Intercont	Piramal Pharma	Wockhardt	Acutaas Chemicals	Rubicon Research
Debt to Equity	0.98	0.55	0.28	0.01	0.13
Short term debt to equity ratio	0.05	0.12	0.11	0.00	0.54
Current Ratio	1.62	1.41	1.55	3.99	1.83
Quick Ratio	1.23	0.77	1.00	2.89	1.00
Interest Coverage	-0.42	0.89	3.04	143.52	11.20

Operating Efficiency Ratios

	Medico Intercont	Piramal Pharma	Wockhardt	Acutaas Chemicals	Rubicon Research
Debtors to sales (%)	32.86	23.05	16.85	22.50	27.51
Asset Turnover	0.86	0.56	0.43	0.81	0.92
Receivable days	106.56	77.05	60.36	90.06	47.59
Inventory Days	37.41	77.13	64.42	61.02	62.58
Payable days	29.29	173.49	218.94	96.06	228.78
Cash Conversion Cycle	114.68	-19.30	-94.15	55.02	-118.62

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.